Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Antimicrobial Stewardship in the Hematopoietic Stem Cell Transplant Population

Antimicrobial Stewardship in the Hematopoietic Stem Cell Transplant Population Curr Treat Options Infect Dis (2018) 10:249–262 DOI 10.1007/s40506-018-0159-7 Antimicrobial Stewardship (A Pakyz, Section Editor) Antimicrobial Stewardship in the Hematopoietic Stem Cell Transplant Population 1,2,* Mary Elizabeth Sexton, MD, MSc 3,4 Amelia A. Langston, MD 1,2 Zanthia Wiley, MD Michael D. Nowak, MD 1,2,6 Jesse T. Jacob, MD, MSc Address *,1 Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, 101 Woodruff Circle, 2101 WMB, Atlanta, 30322, USA Email: marybeth.sexton@emory.edu Emory Antibiotic Resistance Center, Atlanta, USA Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, USA Winship Cancer Institute, Emory University, Atlanta, USA Department of Pathology, Emory University School of Medicine, Atlanta, USA Department of Epidemiology, Emory University School of Public Health, Atlanta, USA Published online: 24 April 2018 * Springer Science+Business Media, LLC, part of Springer Nature 2018 This article is part of the Topical Collection on Antimicrobial Stewardship Keywords Antimicrobial stewardship Hematopoietic stem cell transplant Immunocompromised patients I I Opinion statement Purpose of review Antimicrobial stewardship is important in hematopoietic stem cell transplant (HSCT) recipients because their underlying immunosuppression places them at high risk for life-threatening infectious complications. Limited data exist regarding optimal antimicrobial use in these patients. This review is http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Treatment Options in Infectious Diseases Springer Journals

Antimicrobial Stewardship in the Hematopoietic Stem Cell Transplant Population

Loading next page...
 
/lp/springer_journal/antimicrobial-stewardship-in-the-hematopoietic-stem-cell-transplant-LO21X41AiJ
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Infectious Diseases
eISSN
1534-6250
DOI
10.1007/s40506-018-0159-7
Publisher site
See Article on Publisher Site

Abstract

Curr Treat Options Infect Dis (2018) 10:249–262 DOI 10.1007/s40506-018-0159-7 Antimicrobial Stewardship (A Pakyz, Section Editor) Antimicrobial Stewardship in the Hematopoietic Stem Cell Transplant Population 1,2,* Mary Elizabeth Sexton, MD, MSc 3,4 Amelia A. Langston, MD 1,2 Zanthia Wiley, MD Michael D. Nowak, MD 1,2,6 Jesse T. Jacob, MD, MSc Address *,1 Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, 101 Woodruff Circle, 2101 WMB, Atlanta, 30322, USA Email: marybeth.sexton@emory.edu Emory Antibiotic Resistance Center, Atlanta, USA Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, USA Winship Cancer Institute, Emory University, Atlanta, USA Department of Pathology, Emory University School of Medicine, Atlanta, USA Department of Epidemiology, Emory University School of Public Health, Atlanta, USA Published online: 24 April 2018 * Springer Science+Business Media, LLC, part of Springer Nature 2018 This article is part of the Topical Collection on Antimicrobial Stewardship Keywords Antimicrobial stewardship Hematopoietic stem cell transplant Immunocompromised patients I I Opinion statement Purpose of review Antimicrobial stewardship is important in hematopoietic stem cell transplant (HSCT) recipients because their underlying immunosuppression places them at high risk for life-threatening infectious complications. Limited data exist regarding optimal antimicrobial use in these patients. This review is

Journal

Current Treatment Options in Infectious DiseasesSpringer Journals

Published: Apr 24, 2018

References